July 28, 2022 12:16 ET | Source: ZetrOZ Systems ZetrOZ Systems
TRUMBULL, Conn., July 28, 2022 (GLOBE NEWSWIRE) -- According to a recently published review of medical research, sustained acoustic medicine (SAM) delivered by the sam® device from Zetroz Systems is effective in soft-tissue injury healing, restoring function in patients, and helping them return to work or other normal daily activities.
The study, published in the journal BMC Sports Science, Medicine and Rehabilitation, is a systematic review and meta-analysis to analyze the effects of SAM treatment on musculoskeletal injuries including diathermy (tissue heating), functional outcomes (strength and range of motion), quality of life, pain reduction, and safety profile of the intervention.
The authors reviewed 13 previously published studies involving 372 patients. "Sustained Acoustic Medicine treatment provides tissue heating and tissue recovery, improved patient function and reduction of pain," the authors found. "When patients failed to respond to physical therapy, Sustained Acoustic Medicine proved to be a useful adjunct to facilitate healing and return to work. As a non-invasive and non-narcotic treatment option with an excellent safety profile, Sustained Acoustic Medicine may be considered a good therapeutic option for practitioners."
The study also concluded that sam® performs the following functions:
"This new study supports what we've known from years of research and development and patient experience," said George K. Lewis, Ph.D., and CEO of ZetrOZ Systems. "We hope to see sustained acoustic medicine widely adopted by physicians and health care providers to help even more people with soft tissue healing, reduce pain, and get them back to normal daily activities even faster."
The researchers' summary concurs, suggesting that medical practitioners consider more widespread adoption of SAM. "The data presented in these clinical studies show positive and significant benefit for patients," they wrote. "Furthermore, recent health economic and SAM practitioner survey analysis support medical guideline adoption for SAM as a novel mechanobiological treatment for patient care. SAM treatment, which is widely used in sports medicine, may be considered more broadly as a noninvasive, safe, and effective treatment option for patients with musculoskeletal pain and soft-tissue injuries."
To learn more about ZetrOZ Systems and its innovative health solutions, visit www.zetroz.com.
ZetrOZ Systems is an FDA cGMP and ISO 13585 medical technology company headquartered in the southern coastal region of Connecticut. The organization also has manufacturing facilities across the United States. ZetrOZ Systems produces UltrOZ®, sam®Sport, and sam®Pro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis. Learn more at zetroz.com and samrecover.com.
Buse Kayar buse@newswire.com
Image 1: sam® 2.0 is available for home use to treat common soft tissue injuries
This content was issued through the press release distribution service at Newswire.com.